These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 27771389)

  • 1. Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems.
    Welch SR; Guerrero LW; Chakrabarti AK; McMullan LK; Flint M; Bluemling GR; Painter GR; Nichol ST; Spiropoulou CF; Albariño CG
    Antiviral Res; 2016 Dec; 136():9-18. PubMed ID: 27771389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses.
    Hulseberg CE; Fénéant L; Szymańska-de Wijs KM; Kessler NP; Nelson EA; Shoemaker CJ; Schmaljohn CS; Polyak SJ; White JM
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30700611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An RNA polymerase II-driven Ebola virus minigenome system as an advanced tool for antiviral drug screening.
    Nelson EV; Pacheco JR; Hume AJ; Cressey TN; Deflubé LR; Ruedas JB; Connor JH; Ebihara H; Mühlberger E
    Antiviral Res; 2017 Oct; 146():21-27. PubMed ID: 28807685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant Lassa Virus Expressing Green Fluorescent Protein as a Tool for High-Throughput Drug Screens and Neutralizing Antibody Assays.
    Caì Y; Iwasaki M; Beitzel BF; Yú S; Postnikova EN; Cubitt B; DeWald LE; Radoshitzky SR; Bollinger L; Jahrling PB; Palacios GF; de la Torre JC; Kuhn JH
    Viruses; 2018 Nov; 10(11):. PubMed ID: 30463334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Ebola Virus-Like Particle-Based Reporter System Enables Evaluation of Antiviral Drugs In Vivo under Non-Biosafety Level 4 Conditions.
    Li D; Chen T; Hu Y; Zhou Y; Liu Q; Zhou D; Jin X; Huang Z
    J Virol; 2016 Oct; 90(19):8720-8. PubMed ID: 27440895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses.
    Uebelhoer LS; Albariño CG; McMullan LK; Chakrabarti AK; Vincent JP; Nichol ST; Towner JS
    Antiviral Res; 2014 Jun; 106():86-94. PubMed ID: 24713118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel BSL-2 Lassa virus reverse genetics system modelling the complete viral life cycle.
    Hu X; Bai X; Tian F; Xing Y; Shi Y; Tong Y; Zhong J
    Emerg Microbes Infect; 2024 Dec; 13(1):2356149. PubMed ID: 38747061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput drug screening using the Ebola virus transcription- and replication-competent virus-like particle system.
    Lee N; Shum D; König A; Kim H; Heo J; Min S; Lee J; Ko Y; Choi I; Lee H; Radu C; Hoenen T; Min JY; Windisch MP
    Antiviral Res; 2018 Oct; 158():226-237. PubMed ID: 30149038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lassa Virus Reverse Genetics.
    Martínez-Sobrido L; Paessler S; de la Torre JC
    Methods Mol Biol; 2017; 1602():185-204. PubMed ID: 28508222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening and identification of Lassa virus endonuclease-targeting inhibitors from a fragment-based drug discovery library.
    Lan X; Zhang Y; Jia X; Dong S; Liu Y; Zhang M; Guo J; Cao J; Guo Y; Xiao G; Wang W
    Antiviral Res; 2022 Jan; 197():105230. PubMed ID: 34965446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Lassa virus and Ebola virus infection in host cells treated with the kinase inhibitors genistein and tyrphostin.
    Kolokoltsov AA; Adhikary S; Garver J; Johnson L; Davey RA; Vela EM
    Arch Virol; 2012 Jan; 157(1):121-7. PubMed ID: 21947546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of 2'-deoxy-2'-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus.
    Welch SR; Scholte FEM; Flint M; Chatterjee P; Nichol ST; Bergeron É; Spiropoulou CF
    Antiviral Res; 2017 Nov; 147():91-99. PubMed ID: 29024765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel Ebola virus expressing luciferase allows for rapid and quantitative testing of antivirals.
    Hoenen T; Groseth A; Callison J; Takada A; Feldmann H
    Antiviral Res; 2013 Sep; 99(3):207-13. PubMed ID: 23751367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library.
    Wang P; Liu Y; Zhang G; Wang S; Guo J; Cao J; Jia X; Zhang L; Xiao G; Wang W
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29899092
    [No Abstract]   [Full Text] [Related]  

  • 15. Simultaneous screening for selective SARS-CoV-2, Lassa, and Machupo virus entry inhibitors.
    Otsuka Y; Zhang L; Mou H; Shumate J; Kitzmiller CE; Scampavia L; Bannister TD; Farzan M; Choe H; Spicer TP
    SLAS Discov; 2024 Sep; 29(6):100178. PubMed ID: 39159824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A high throughput screen identifies benzoquinoline compounds as inhibitors of Ebola virus replication.
    Luthra P; Liang J; Pietzsch CA; Khadka S; Edwards MR; Wei S; De S; Posner B; Bukreyev A; Ready JM; Basler CF
    Antiviral Res; 2018 Feb; 150():193-201. PubMed ID: 29294299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.
    Safronetz D; Rosenke K; Westover JB; Martellaro C; Okumura A; Furuta Y; Geisbert J; Saturday G; Komeno T; Geisbert TW; Feldmann H; Gowen BB
    Sci Rep; 2015 Oct; 5():14775. PubMed ID: 26456301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunobiology of Ebola and Lassa virus infections.
    Prescott JB; Marzi A; Safronetz D; Robertson SJ; Feldmann H; Best SM
    Nat Rev Immunol; 2017 Mar; 17(3):195-207. PubMed ID: 28111475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methanol Fixation, but not Giemsa Staining, Inactivates Ebola and Lassa Viruses in Peripheral Blood Smears Made on Plastic Microscope Slides.
    Relich RF; Feldmann H; Haddock E
    Am J Trop Med Hyg; 2020 Nov; 103(5):2085-2090. PubMed ID: 32959767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination and Therapeutic Exploitation of Ebola Virus Spontaneous Mutation Frequency.
    Alfson KJ; Worwa G; Carrion R; Griffiths A
    J Virol; 2015 Dec; 90(5):2345-55. PubMed ID: 26676781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.